Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Polymers allergy, Rash, SARS-CoV-2 test
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of GLAUCOMA (glaucoma with increased eye pressure) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 070H21A, 022C21A and 037BZ1A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. Concurrent medical conditions included Glaucoma. On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Dec-2021, the patient experienced RASH (Rash returned more severe this time affecting her left eye, hands and between fingers). On 30-Dec-2021, after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (tested positive for COVID-19). On an unknown date, the patient experienced POLYMERS ALLERGY (allergy to plastic/ allergy to polyester), ALLERGY TO METALS (Allergy to nickel), ALLERGY TO CHEMICALS (Allergy to fragrance), ALLERGY TO CHEMICALS (Allergy to dye), OCULAR DISCOMFORT (the medication for rash affected her glaucoma with increased eye pressure), GLAUCOMA (glaucoma with increased eye pressure) (seriousness criterion medically significant) and VACCINATION FAILURE (Vaccination failure). At the time of the report, POLYMERS ALLERGY (allergy to plastic/ allergy to polyester), ALLERGY TO METALS (Allergy to nickel), ALLERGY TO CHEMICALS (Allergy to fragrance), ALLERGY TO CHEMICALS (Allergy to dye), OCULAR DISCOMFORT (the medication for rash affected her glaucoma with increased eye pressure), RASH (Rash returned more severe this time affecting her left eye, hands and between fingers), COVID-19 (tested positive for COVID-19), GLAUCOMA (glaucoma with increased eye pressure) and VACCINATION FAILURE (Vaccination failure) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 30-Dec-2021, SARS-CoV-2 test: positive (Positive) Positive. No concomitant medications were reported. No treatment medications were reported. Patient reported that the medication for rash affected her glaucoma with increased eye pressure so she had to find medication replacement. She has also reported that she has end up getting tacrolimus with delay in January of 2022 which worsen her eye condition and therefore she needs eye operation very soon. She reported that HCP is looking for medication that does not worsen eye condition and cause kidney damage. COMPANY COMMENT: This is a Spontaneous case concerning a 60-years-old female patient with clinical history of Glaucoma, COVID-19 immunisation: mRNA-1273 on 9-april and 7 May, 2021, SARS-CoV-2 test: positive on 30-Dec-2021 who experienced the unexpected events  of POLYMERS ALLERGY,  ALLERGY TO METALS, ALLERGY TO CHEMICALS (fragrance), ALLERGY TO CHEMICALS (dye), OCULAR DISCOMFORT, RASH, COVID-19 (AESI). CONDITION AGGRAVATE (glaucoma) and VACCINATION FAILURE beginning 1 days after 3rd  dose of mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Terms and onset were captured as provided. This case was linked to MOD-2022-533329 (Patient Link). Sender's Comments: COMPANY COMMENT: This is a Spontaneous case concerning a 60-years-old female patient with clinical history of Glaucoma, COVID-19 immunisation: mRNA-1273 on 9-April and 7 May, 2021, SARS-CoV-2 test: positive on 30-Dec-2021 who experienced the unexpected events  of POLYMERS ALLERGY,  ALLERGY TO METALS, ALLERGY TO CHEMICALS (fragrance), ALLERGY TO CHEMICALS (dye), OCULAR DISCOMFORT, RASH, COVID-19 (AESI). CONDITION AGGRAVATE (glaucoma) and VACCINATION FAILURE beginning 1 days after 3rd  dose of mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Terms and onset were captured as provided.